{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:07:47Z","timestamp":1788919667140,"version":"build-2803163510"},"publisher-location":"Cham","reference-count":85,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783031051173","type":"print"},{"value":"9783031051180","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/164_2021_553","type":"book-chapter","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T21:02:53Z","timestamp":1643403773000},"page":"53-72","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Mechanistic Target of Rapamycin (mTOR) Inhibitors"],"prefix":"10.1007","author":[{"given":"Denise","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard J.","family":"Eisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,29]]},"reference":[{"issue":"12","key":"553_CR1","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1097\/tp.0b013e3182708e56","volume":"94","author":"J Andrassy","year":"2012","unstructured":"Andrassy J et al (2012) Is cytomegalovirus prophylaxis dispensable in patients receiving an MTOR inhibitor\u2013based immunosuppression? A systematic review and meta-analysis. Transp J 94(12):1208\u20131217. https:\/\/doi.org\/10.1097\/tp.0b013e3182708e56","journal-title":"Transp J"},{"issue":"6","key":"553_CR2","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/s1470-2045(14)70138-x","volume":"15","author":"F Andr\u00e9","year":"2014","unstructured":"Andr\u00e9 F et al (2014) Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 15(6):580\u2013591. https:\/\/doi.org\/10.1016\/s1470-2045(14)70138-x","journal-title":"Lancet Oncol"},{"issue":"9","key":"553_CR3","doi-asserted-by":"publisher","first-page":"e004050","DOI":"10.1161\/CIRCHEARTFAILURE.117.004050","volume":"11","author":"S Arora","year":"2018","unstructured":"Arora S, Andreassen AK, Karason K et al (2018) Effect of everolimus initiation and calcineurin inhibitor elimination on cardiac allograft vasculopathy in de novo heart transplant recipients. Circ Heart Fail 11(9):e004050","journal-title":"Circ Heart Fail"},{"issue":"11","key":"553_CR4","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/s0735-1097(17)34086-x","volume":"69","author":"R Asleh","year":"2017","unstructured":"Asleh R et al (2017) Sirolimus-based immunosuppression mitigates progression of cardiac allograft vasculopathy and improves cardiac outcomes after heart transplantation: a single center 15-year follow-up study. J Am Coll Cardiol 69(11):697. https:\/\/doi.org\/10.1016\/s0735-1097(17)34086-x","journal-title":"J Am Coll Cardiol"},{"key":"553_CR5","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.jacc.2017.12.005","volume":"71","author":"R Asleh","year":"2018","unstructured":"Asleh R, Briasoulis A, Kremers WK et al (2018) Long-term sirolimus for primary immunosuppression in heart transplant recipients. J Am Coll Cardiol 71:636\u2013650","journal-title":"J Am Coll Cardiol"},{"key":"553_CR6","doi-asserted-by":"publisher","unstructured":"Asleh R, Alnsasra H, Lerman A et al (2020) Effects of mTOR inhibitor-related proteinuria on progression of cardiac allograft vasculopathy and outcomes among heart transplant recipients. Am J Transplant. https:\/\/doi.org\/10.1111\/ajt.16155","DOI":"10.1111\/ajt.16155"},{"issue":"11","key":"553_CR7","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1111\/ajt.15361","volume":"19","author":"MJ Barten","year":"2019","unstructured":"Barten MJ, Hirt SW, Garbade J et al (2019) Comparing everolimus-based immunosuppression with reduction or withdrawal of calcineurin inhibitor reduction from six months after heart transplantation: the randomized MANDELA study. Am J Transplant 19(11):3006\u20133017. https:\/\/doi.org\/10.1111\/ajt.15361","journal-title":"Am J Transplant"},{"issue":"6","key":"553_CR8","doi-asserted-by":"publisher","first-page":"651","DOI":"10.2217\/fon.12.49","volume":"8","author":"JA Beaver","year":"2012","unstructured":"Beaver JA, Park BH (2012) The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. Future Oncol 8(6):651\u2013657. https:\/\/doi.org\/10.2217\/fon.12.49","journal-title":"Future Oncol"},{"issue":"3","key":"553_CR9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/oby.2000.29","volume":"8","author":"A Bell","year":"2000","unstructured":"Bell A et al (2000) Rapamycin inhibits human adipocyte differentiation in primary culture. Obes Res 8(3):249\u2013254. https:\/\/doi.org\/10.1038\/oby.2000.29","journal-title":"Obes Res"},{"issue":"11","key":"553_CR10","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/nrd3531","volume":"10","author":"D Benjamin","year":"2011","unstructured":"Benjamin D et al (2011) Rapamycin passes the torch: a new generation of MTOR inhibitors. Nat Rev Drug Discov 10(11):868\u2013880. https:\/\/doi.org\/10.1038\/nrd3531","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"553_CR11","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1097\/01.tp.0000177644.45192.a3","volume":"81","author":"R Bestetti","year":"2006","unstructured":"Bestetti R et al (2006) Switch from calcineurin inhibitors to sirolimus-induced renal recovery in heart transplant recipients in the midterm follow-up. Transplantation 81(5):692\u2013696. https:\/\/doi.org\/10.1097\/01.tp.0000177644.45192.a3","journal-title":"Transplantation"},{"issue":"2","key":"553_CR12","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/nejmoa063564","volume":"358","author":"JJ Bissler","year":"2008","unstructured":"Bissler JJ et al (2008) Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358(2):140\u2013151. https:\/\/doi.org\/10.1056\/nejmoa063564","journal-title":"N Engl J Med"},{"issue":"9869","key":"553_CR13","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/s0140-6736(12)61767-x","volume":"381","author":"JJ Bissler","year":"2013","unstructured":"Bissler JJ et al (2013) Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 381(9869):817\u2013824. https:\/\/doi.org\/10.1016\/s0140-6736(12)61767-x","journal-title":"Lancet"},{"issue":"1","key":"553_CR14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/ndt\/gfv249","volume":"31","author":"JJ Bissler","year":"2015","unstructured":"Bissler JJ et al (2015) Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. Nephrol Dial Transplant 31(1):111\u2013119. https:\/\/doi.org\/10.1093\/ndt\/gfv249","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"553_CR15","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrn3068","volume":"12","author":"J Bov\u00e9","year":"2011","unstructured":"Bov\u00e9 J et al (2011) Fighting neurodegeneration with rapamycin: mechanistic insights. Nat Rev Neurosci 12(8):437\u2013452. https:\/\/doi.org\/10.1038\/nrn3068","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"553_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11523-011-0167-8","volume":"6","author":"JS Carew","year":"2011","unstructured":"Carew JS et al (2011) Mechanisms of MTOR inhibitor resistance in cancer therapy. Target Oncol 6(1):17\u201327. https:\/\/doi.org\/10.1007\/s11523-011-0167-8","journal-title":"Target Oncol"},{"issue":"7","key":"553_CR17","doi-asserted-by":"publisher","first-page":"505","DOI":"10.7326\/0003-4819-144-7-200604040-00009","volume":"144","author":"L Champion","year":"2006","unstructured":"Champion L et al (2006) Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann Intern Med 144(7):505. https:\/\/doi.org\/10.7326\/0003-4819-144-7-200604040-00009","journal-title":"Ann Intern Med"},{"issue":"45","key":"553_CR18","doi-asserted-by":"publisher","first-page":"17414","DOI":"10.1073\/pnas.0809136105","volume":"105","author":"AY Choo","year":"2008","unstructured":"Choo AY et al (2008) Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of MRNA translation. Proc Natl Acad Sci 105(45):17414\u201317419. https:\/\/doi.org\/10.1073\/pnas.0809136105","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"553_CR19","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00147-004-0700-0","volume":"17","author":"E Dittrich","year":"2004","unstructured":"Dittrich E et al (2004) Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. Transpl Int 17(4):215\u2013220. https:\/\/doi.org\/10.1007\/s00147-004-0700-0","journal-title":"Transpl Int"},{"issue":"9","key":"553_CR20","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1056\/nejmoa022171","volume":"349","author":"HJ Eisen","year":"2003","unstructured":"Eisen HJ et al (2003) Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349(9):847\u2013858. https:\/\/doi.org\/10.1056\/nejmoa022171","journal-title":"N Engl J Med"},{"issue":"5","key":"553_CR21","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1111\/ajt.12181","volume":"13","author":"HJ Eisen","year":"2013","unstructured":"Eisen HJ et al (2013) Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial. Am J Transplant 13(5):1203\u20131216. https:\/\/doi.org\/10.1111\/ajt.12181","journal-title":"Am J Transplant"},{"key":"553_CR22","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.jacc.2017.12.033","volume":"71","author":"HJ Eisen","year":"2018","unstructured":"Eisen HJ, Hasni SF, Wang D (2018) The return of the mTOR inhibitors: getting it right in patients after cardiac transplantation. J Am Coll Cardiol 71:651\u2013653","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"553_CR23","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1056\/nejmoa1204166","volume":"367","author":"S Euvrard","year":"2012","unstructured":"Euvrard S et al (2012) Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 367(4):329\u2013339. https:\/\/doi.org\/10.1056\/nejmoa1204166","journal-title":"N Engl J Med"},{"issue":"9","key":"553_CR24","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.1016\/j.transproceed.2005.09.152","volume":"37","author":"M Fernandez-Valls","year":"2005","unstructured":"Fernandez-Valls M et al (2005) Sirolimus as an alternative to anticalcineurin therapy in heart transplantation: experience of a single center. Transplant Proc 37(9):4021\u20134023. https:\/\/doi.org\/10.1016\/j.transproceed.2005.09.152","journal-title":"Transplant Proc"},{"issue":"11","key":"553_CR25","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1111\/j.1600-6143.2004.00627.x","volume":"4","author":"SM Flechner","year":"2004","unstructured":"Flechner SM et al (2004) De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 4(11):1776\u20131785. https:\/\/doi.org\/10.1111\/j.1600-6143.2004.00627.x","journal-title":"Am J Transplant"},{"issue":"9861","key":"553_CR26","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/s0140-6736(12)61134-9","volume":"381","author":"DN Franz","year":"2013","unstructured":"Franz DN et al (2013) Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 381(9861):125\u2013132. https:\/\/doi.org\/10.1016\/s0140-6736(12)61134-9","journal-title":"Lancet"},{"issue":"10056","key":"553_CR27","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/s0140-6736(16)31419-2","volume":"388","author":"JA French","year":"2016","unstructured":"French JA et al (2016) Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet 388(10056):2153\u20132163. https:\/\/doi.org\/10.1016\/s0140-6736(16)31419-2","journal-title":"Lancet"},{"issue":"7","key":"553_CR28","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.healun.2013.04.010","volume":"32","author":"B Ghassemieh","year":"2013","unstructured":"Ghassemieh B et al (2013) Decreased incidence of cytomegalovirus infection with sirolimus in a post hoc randomized, multicenter study in lung transplantation. J Heart Lung Transplant 32(7):701\u2013706. https:\/\/doi.org\/10.1016\/j.healun.2013.04.010","journal-title":"J Heart Lung Transplant"},{"issue":"3","key":"553_CR29","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ejcts.2003.11.030","volume":"25","author":"J Groetzner","year":"2004","unstructured":"Groetzner J et al (2004) Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients. Eur J Cardiothorac Surg 25(3):333\u2013341. https:\/\/doi.org\/10.1016\/j.ejcts.2003.11.030","journal-title":"Eur J Cardiothorac Surg"},{"issue":"2","key":"553_CR30","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/tp.0b013e3181e11798","volume":"90","author":"M Guba","year":"2010","unstructured":"Guba M et al (2010) Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial. Transp J 90(2):175\u2013183. https:\/\/doi.org\/10.1097\/tp.0b013e3181e11798","journal-title":"Transp J"},{"issue":"10","key":"553_CR31","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.healun.2007.07.034","volume":"26","author":"F Gustafsson","year":"2007","unstructured":"Gustafsson F et al (2007) Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction. J Heart Lung Transplant 26(10):998\u20131003. https:\/\/doi.org\/10.1016\/j.healun.2007.07.034","journal-title":"J Heart Lung Transplant"},{"issue":"2","key":"553_CR32","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/s0092-8674(02)00833-4","volume":"110","author":"K Hara","year":"2002","unstructured":"Hara K et al (2002) Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110(2):177\u2013189. https:\/\/doi.org\/10.1016\/s0092-8674(02)00833-4","journal-title":"Cell"},{"issue":"9","key":"553_CR33","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1592\/phco.24.13.1159.38094","volume":"24","author":"KL Hardinger","year":"2004","unstructured":"Hardinger KL et al (2004) Current and future immunosuppressive strategies in renal transplantation. Pharmacotherapy 24(9):1159\u20131176. https:\/\/doi.org\/10.1592\/phco.24.13.1159.38094","journal-title":"Pharmacotherapy"},{"issue":"11","key":"553_CR34","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1097\/00007890-200106150-00016","volume":"71","author":"JC Hong","year":"2001","unstructured":"Hong JC, Kahan BD (2001) Sirolimus rescue therapy for refractory rejection in renal transplantation1,2. Transplantation 71(11):1579\u20131584. https:\/\/doi.org\/10.1097\/00007890-200106150-00016","journal-title":"Transplantation"},{"issue":"1","key":"553_CR35","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1042\/bst0370217","volume":"37","author":"J Huang","year":"2009","unstructured":"Huang J, Manning BD (2009) A complex interplay between Akt, TSC2 and the two MTOR complexes. Biochem Soc Trans 37(1):217\u2013222. https:\/\/doi.org\/10.1042\/bst0370217","journal-title":"Biochem Soc Trans"},{"issue":"11","key":"553_CR36","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1016\/j.healun.2005.02.018","volume":"24","author":"J Hunt","year":"2005","unstructured":"Hunt J et al (2005) Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation. J Heart Lung Transplant 24(11):1863\u20131867. https:\/\/doi.org\/10.1016\/j.healun.2005.02.018","journal-title":"J Heart Lung Transplant"},{"issue":"5","key":"553_CR37","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.tibs.2013.01.004","volume":"38","author":"JL Jewell","year":"2013","unstructured":"Jewell JL, Guan K-L (2013) Nutrient signaling to MTOR and cell growth. Trends Biochem Sci 38(5):233\u2013242. https:\/\/doi.org\/10.1016\/j.tibs.2013.01.004","journal-title":"Trends Biochem Sci"},{"issue":"7432","key":"553_CR38","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nature11861","volume":"493","author":"SC Johnson","year":"2013","unstructured":"Johnson SC et al (2013a) MTOR is a key modulator of ageing and age-related disease. Nature 493(7432):338\u2013345. https:\/\/doi.org\/10.1038\/nature11861","journal-title":"Nature"},{"issue":"6165","key":"553_CR39","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1126\/science.1244360","volume":"342","author":"SC Johnson","year":"2013","unstructured":"Johnson SC et al (2013b) MTOR inhibition alleviates mitochondrial disease in a mouse model of leigh syndrome. Science 342(6165):1524\u20131528. https:\/\/doi.org\/10.1126\/science.1244360","journal-title":"Science"},{"issue":"7","key":"553_CR40","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1681\/asn.2007111202","volume":"19","author":"O Johnston","year":"2008","unstructured":"Johnston O et al (2008) Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 19(7):1411\u20131418. https:\/\/doi.org\/10.1681\/asn.2007111202","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"553_CR41","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/s0009-9236(98)90120-5","volume":"63","author":"B Kaplan","year":"1998","unstructured":"Kaplan B et al (1998) The effects of relative timing of Sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent. Clin Pharmacol Ther 63(1):48\u201353. https:\/\/doi.org\/10.1016\/s0009-9236(98)90120-5","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"553_CR42","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1111\/j.1600-6143.2008.02272.x","volume":"8","author":"BL Kasiske","year":"2008","unstructured":"Kasiske BL et al (2008) Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant 8(7):1384\u20131392. https:\/\/doi.org\/10.1111\/j.1600-6143.2008.02272.x","journal-title":"Am J Transplant"},{"issue":"17","key":"553_CR43","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1161\/01.cir.0000136812.90177.94","volume":"110","author":"A Keogh","year":"2004","unstructured":"Keogh A et al (2004) Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years. Circulation 110(17):2694\u20132700. https:\/\/doi.org\/10.1161\/01.cir.0000136812.90177.94","journal-title":"Circulation"},{"issue":"2","key":"553_CR44","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/s0092-8674(02)00808-5","volume":"110","author":"D-H Kim","year":"2002","unstructured":"Kim D-H et al (2002) MTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110(2):163\u2013175. https:\/\/doi.org\/10.1016\/s0092-8674(02)00808-5","journal-title":"Cell"},{"key":"553_CR45","doi-asserted-by":"publisher","first-page":"g6679","DOI":"10.1136\/bmj.g6679","volume":"349","author":"GA Knoll","year":"2014","unstructured":"Knoll GA et al (2014) Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ 349:g6679. https:\/\/doi.org\/10.1136\/bmj.g6679","journal-title":"BMJ"},{"issue":"6","key":"553_CR46","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1093\/annonc\/mdx075","volume":"28","author":"JJ Knox","year":"2017","unstructured":"Knox JJ et al (2017) Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Ann Oncol 28(6):1339\u20131345. https:\/\/doi.org\/10.1093\/annonc\/mdx075","journal-title":"Ann Oncol"},{"issue":"5","key":"553_CR47","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.jchf.2013.07.002","volume":"1","author":"JA Kobashigawa","year":"2013","unstructured":"Kobashigawa JA et al (2013) Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients. J Am Coll Cardiol HF 1(5):389\u2013399. https:\/\/doi.org\/10.1016\/j.jchf.2013.07.002","journal-title":"J Am Coll Cardiol HF"},{"issue":"5","key":"553_CR48","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/s0026-0495(98)90239-6","volume":"47","author":"FB Kraemer","year":"1998","unstructured":"Kraemer FB et al (1998) Insulin regulates lipoprotein lipase activity in rat adipose cells via wortmannin- and rapamycin-sensitive pathways. Metabolism 47(5):555\u2013559. https:\/\/doi.org\/10.1016\/s0026-0495(98)90239-6","journal-title":"Metabolism"},{"issue":"6","key":"553_CR49","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.2337\/db06-1016","volume":"56","author":"M Krebs","year":"2007","unstructured":"Krebs M et al (2007) The mammalian target of rapamycin pathway regulates nutrient-sensitive glucose uptake in man. Diabetes 56(6):1600\u20131607. https:\/\/doi.org\/10.2337\/db06-1016","journal-title":"Diabetes"},{"issue":"12","key":"553_CR50","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/j.healun.2005.08.015","volume":"24","author":"SS Kushwaha","year":"2005","unstructured":"Kushwaha SS et al (2005) Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor\u2013induced nephrotoxicity. J Heart Lung Transplant 24(12):2129\u20132136. https:\/\/doi.org\/10.1016\/j.healun.2005.08.015","journal-title":"J Heart Lung Transplant"},{"issue":"2","key":"553_CR51","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante M, Sabatini DM (2012) MTOR signaling in growth control and disease. Cell 149(2):274\u2013293. https:\/\/doi.org\/10.1016\/j.cell.2012.03.017","journal-title":"Cell"},{"issue":"9","key":"553_CR52","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1097\/01.tp.0000185200.17589.74","volume":"80","author":"E Letavernier","year":"2005","unstructured":"Letavernier E et al (2005) Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 80(9):1198\u20131203. https:\/\/doi.org\/10.1097\/01.tp.0000185200.17589.74","journal-title":"Transplantation"},{"issue":"2","key":"553_CR53","doi-asserted-by":"publisher","first-page":"326","DOI":"10.2215\/cjn.03751106","volume":"2","author":"E Letavernier","year":"2007","unstructured":"Letavernier E et al (2007) High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2(2):326\u2013333. https:\/\/doi.org\/10.2215\/cjn.03751106","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"553_CR54","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1111\/ajt.12795","volume":"14","author":"WH Lim","year":"2014","unstructured":"Lim WH et al (2014) A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients. Am J Transplant 14(9):2106\u20132119. https:\/\/doi.org\/10.1111\/ajt.12795","journal-title":"Am J Transplant"},{"issue":"5","key":"553_CR55","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrm2672","volume":"10","author":"XM Ma","year":"2009","unstructured":"Ma XM, Blenis J (2009) Molecular mechanisms of MTOR-mediated translational control. Nat Rev Mol Cell Biol 10(5):307\u2013318. https:\/\/doi.org\/10.1038\/nrm2672","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"10","key":"553_CR56","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1111\/j.1600-6143.2005.01051.x","volume":"5","author":"AJ Matas","year":"2005","unstructured":"Matas AJ et al (2005) Prednisone-free maintenance immunosuppression-a 5-year experience. Am J Transplant 5(10):2473\u20132478. https:\/\/doi.org\/10.1111\/j.1600-6143.2005.01051.x","journal-title":"Am J Transplant"},{"issue":"3","key":"553_CR57","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1056\/nejmc1106358","volume":"365","author":"FX McCormack","year":"2011","unstructured":"McCormack FX (2011) Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 365(3):271\u2013272. https:\/\/doi.org\/10.1056\/nejmc1106358","journal-title":"N Engl J Med"},{"key":"553_CR58","doi-asserted-by":"publisher","unstructured":"Menon S, Manning BD (2008) Common corruption of the MTOR signaling network in human tumors. Oncogene 27(S2). https:\/\/doi.org\/10.1038\/onc.2009.352","DOI":"10.1038\/onc.2009.352"},{"issue":"9637","key":"553_CR59","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/s0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449\u2013456. https:\/\/doi.org\/10.1016\/s0140-6736(08)61039-9","journal-title":"Lancet"},{"issue":"1","key":"553_CR60","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/ki.1996.28","volume":"49","author":"MG Murgia","year":"1996","unstructured":"Murgia MG et al (1996) The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 49(1):209\u2013216. https:\/\/doi.org\/10.1038\/ki.1996.28","journal-title":"Kidney Int"},{"issue":"11","key":"553_CR61","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1097\/tp.0b013e31824810e6","volume":"93","author":"B Nashan","year":"2012","unstructured":"Nashan B et al (2012) Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transp J 93(11):1075\u20131085. https:\/\/doi.org\/10.1097\/tp.0b013e31824810e6","journal-title":"Transp J"},{"issue":"8","key":"553_CR62","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1172\/JCI67674","volume":"123","author":"F Neff","year":"2013","unstructured":"Neff F et al (2013) Rapamycin extends murine lifespan but has limited effects on aging. J Clin Invest 123(8):3272\u20133291. https:\/\/doi.org\/10.1172\/JCI67674","journal-title":"J Clin Invest"},{"issue":"2","key":"553_CR63","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1517\/14740338.2013.752814","volume":"12","author":"N Pallet","year":"2012","unstructured":"Pallet N, Legendre C (2012) Adverse events associated with MTOR inhibitors. Expert Opin Drug Saf 12(2):177\u2013186. https:\/\/doi.org\/10.1517\/14740338.2013.752814","journal-title":"Expert Opin Drug Saf"},{"key":"553_CR64","volume-title":"Torisel (temsirolimus) injection","author":"Product Information","year":"2011","unstructured":"Product Information (2011) Torisel (temsirolimus) injection. Pfizer Inc., Wyeth Pharmaceuticals LLC, Philadelphia"},{"key":"553_CR65","volume-title":"Afinitor (everolimus) tablets","author":"Product Information","year":"2012","unstructured":"Product Information (2012) Afinitor (everolimus) tablets. Novartis Pharmaceutical Corporation, East Hanover"},{"key":"553_CR66","volume-title":"Rapamune (sirolimus) oral solution and tablets","author":"Product Information","year":"2018","unstructured":"Product Information (2018) Rapamune (sirolimus) oral solution and tablets. Pfizer Inc., Wyeth Pharmaceuticals LLC, Philadelphia"},{"issue":"4","key":"553_CR67","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/01.tp.0000276959.56959.69","volume":"84","author":"E Raichlin","year":"2007","unstructured":"Raichlin E et al (2007) Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients. Transplantation 84(4):467\u2013474. https:\/\/doi.org\/10.1097\/01.tp.0000276959.56959.69","journal-title":"Transplantation"},{"issue":"7","key":"553_CR68","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1093\/annonc\/mdv170","volume":"26","author":"A Ravaud","year":"2015","unstructured":"Ravaud A et al (2015) RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon \u03b1-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 26(7):1378\u20131384. https:\/\/doi.org\/10.1093\/annonc\/mdv170","journal-title":"Ann Oncol"},{"issue":"9","key":"553_CR69","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1097\/00007890-200005150-00034","volume":"69","author":"M Sabbatini","year":"2000","unstructured":"Sabbatini M et al (2000) Acute effects of rapamycin on glomerular dynamics: a micropuncture study in the rat. Transplantation 69(9):1946\u20131949. https:\/\/doi.org\/10.1097\/00007890-200005150-00034","journal-title":"Transplantation"},{"issue":"14","key":"553_CR70","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.cub.2004.06.054","volume":"14","author":"DD Sarbassov","year":"2004","unstructured":"Sarbassov DD et al (2004) Rictor, a novel binding partner of MTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14(14):1296\u20131302. https:\/\/doi.org\/10.1016\/j.cub.2004.06.054","journal-title":"Curr Biol"},{"issue":"3","key":"553_CR71","doi-asserted-by":"publisher","first-page":"7S","DOI":"10.1016\/s0041-1345(03)00211-2","volume":"35","author":"SN Sehgal","year":"2003","unstructured":"Sehgal SN (2003) Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 35(3):7S\u201314S. https:\/\/doi.org\/10.1016\/s0041-1345(03)00211-2","journal-title":"Transplant Proc"},{"issue":"11","key":"553_CR72","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1097\/01.tp.0000184623.35773.6a","volume":"80","author":"JJ Sennesael","year":"2005","unstructured":"Sennesael JJ et al (2005) Conversion from cyclosporine to sirolimus in stable renal transplant recipients. Transplantation 80(11):1578\u20131585. https:\/\/doi.org\/10.1097\/01.tp.0000184623.35773.6a","journal-title":"Transplantation"},{"issue":"23","key":"553_CR73","doi-asserted-by":"publisher","first-page":"3831","DOI":"10.4161\/cc.8.23.10070","volume":"8","author":"B Shor","year":"2009","unstructured":"Shor B et al (2009) Targeting MTOR globally in cancer: thinking beyond rapamycin. Cell Cycle 8(23):3831\u20133837. https:\/\/doi.org\/10.4161\/cc.8.23.10070","journal-title":"Cell Cycle"},{"issue":"13","key":"553_CR74","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa042831","volume":"352","author":"G Stallone","year":"2005","unstructured":"Stallone G et al (2005) Sirolimus for Kaposi\u2019s sarcoma in renal-transplant recipients. N Engl J Med 352(13):1317\u20131323. https:\/\/doi.org\/10.1056\/NEJMoa042831","journal-title":"N Engl J Med"},{"issue":"4","key":"553_CR75","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1097\/tp.0b013e3181636061","volume":"85","author":"GH Steele","year":"2008","unstructured":"Steele GH et al (2008) Pericardial effusion coincident with Sirolimus therapy: a review of Wyeth\u02bcs safety database. Transplantation 85(4):645\u2013647. https:\/\/doi.org\/10.1097\/tp.0b013e3181636061","journal-title":"Transplantation"},{"issue":"7","key":"553_CR76","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1097\/01.tp.0000176482.63122.03","volume":"80","author":"E Sulanc","year":"2005","unstructured":"Sulanc E et al (2005) New-onset diabetes after kidney transplantation: an application of 2003 international guidelines. Transplantation 80(7):945\u2013952. https:\/\/doi.org\/10.1097\/01.tp.0000176482.63122.03","journal-title":"Transplantation"},{"issue":"5","key":"553_CR77","doi-asserted-by":"publisher","first-page":"725","DOI":"10.4161\/auto.5.5.8504","volume":"5","author":"CC Thoreen","year":"2009","unstructured":"Thoreen CC, Sabatini DM (2009) Rapamycin inhibits mTORC1, but not completely. Autophagy 5(5):725\u2013726. https:\/\/doi.org\/10.4161\/auto.5.5.8504","journal-title":"Autophagy"},{"key":"553_CR78","doi-asserted-by":"publisher","unstructured":"Toi M et al (2017) Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2 advanced breast cancer in BOLERO-1. Breast Cancer Res 19(1). https:\/\/doi.org\/10.1186\/s13058-017-0839-0","DOI":"10.1186\/s13058-017-0839-0"},{"issue":"41","key":"553_CR79","doi-asserted-by":"publisher","first-page":"38052","DOI":"10.1074\/jbc.M106703200","volume":"276","author":"F Tremblay","year":"2001","unstructured":"Tremblay F, Marette A (2001) Amino acid and insulin signaling via the mTOR\/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells. J Biol Chem 276(41):38052\u201338060. https:\/\/doi.org\/10.1074\/jbc.M106703200","journal-title":"J Biol Chem"},{"issue":"4","key":"553_CR80","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1172\/jci44145","volume":"121","author":"SA Wander","year":"2011","unstructured":"Wander SA et al (2011) Next-generation MTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Investig 121(4):1231\u20131241. https:\/\/doi.org\/10.1172\/jci44145","journal-title":"J Clin Investig"},{"issue":"12","key":"553_CR81","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1093\/ndt\/gfm420","volume":"22","author":"SM Weiner","year":"2007","unstructured":"Weiner SM et al (2007) Pneumonitis associated with sirolimus: clinical characteristics, risk factors and outcome a single-centre experience and review of the literature. Nephrol Dial Transplant 22(12):3631\u20133637. https:\/\/doi.org\/10.1093\/ndt\/gfm420","journal-title":"Nephrol Dial Transplant"},{"key":"553_CR82","doi-asserted-by":"publisher","unstructured":"Yang L et al (2018) RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis. BMC Cancer 18(1). https:\/\/doi.org\/10.1186\/s12885-018-4091-5","DOI":"10.1186\/s12885-018-4091-5"},{"issue":"9","key":"553_CR83","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1002\/cam4.487","volume":"4","author":"EL Yanik","year":"2015","unstructured":"Yanik EL et al (2015) Sirolimus effects on cancer incidence after kidney transplantation: a meta-analysis. Cancer Med 4(9):1448\u20131459. https:\/\/doi.org\/10.1002\/cam4.487","journal-title":"Cancer Med"},{"issue":"8","key":"553_CR84","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1158\/0008-5472.can-10-4158","volume":"71","author":"JL Yecies","year":"2011","unstructured":"Yecies JL, Manning BD (2011) Transcriptional control of cellular metabolism by MTOR signaling. Cancer Res 71(8):2815\u20132820. https:\/\/doi.org\/10.1158\/0008-5472.can-10-4158","journal-title":"Cancer Res"},{"issue":"1","key":"553_CR85","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1089\/lrb.2009.0020","volume":"8","author":"J Yu","year":"2010","unstructured":"Yu J, Henske EP (2010) MTOR activation, lymphangiogenesis, and estrogen-mediated cell survival: the \u2018perfect storm\u2019 of pro-metastatic factors in LAM pathogenesis. Lymphat Res Biol 8(1):43\u201349. https:\/\/doi.org\/10.1089\/lrb.2009.0020","journal-title":"Lymphat Res Biol"}],"container-title":["Handbook of Experimental Pharmacology","Pharmacology of Immunosuppression"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2021_553","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T07:04:39Z","timestamp":1657091079000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/164_2021_553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9783031051173","9783031051180"],"references-count":85,"URL":"https:\/\/doi.org\/10.1007\/164_2021_553","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"29 January 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}